AveXis Community Update on Submitting their Application for AVXS-101

19 October 2018

AveXis yesterday submitted their regulatory applications for AVXS-101 in the U.S., Europe and Japan for use in infants with SMA Type 1. This is an important initial step toward the potential approval of AVXS-101, a gene replacement therapy candidate for the treatment of the underlying root cause of SMA.

Read the Community Update